<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203735</url>
  </required_header>
  <id_info>
    <org_study_id>SOR507910CTIL</org_study_id>
    <nct_id>NCT01203735</nct_id>
  </id_info>
  <brief_title>Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer</brief_title>
  <official_title>Valproic Acid in Combination With Concurrent Chemoradiotherapy Using Vinorelbine and Cisplatin for Inoperable Locally Advanced Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is non-randomized phase 2 study to evaluate toxicity and efficacy of VA with concurrent
      chemoradiotherapy (CCRT) containing weekly vinorelbine and cisplatin in patients with locally
      advanced inoperable non-small-cell lung cancer (NSCLC).All patients will be planned for
      three-dimensional conformal RT (3-DCRT). Concurrent weekly vinorelbine and cisplatin and oral
      valproic acid (VA)will be started at the first day of RT. Follow up will be conducted every 3
      months after completion of the study treatment. Toxicity will be assessed using CTCAE, based
      on clinical examination and laboratory tests during the study treatment and at follow up
      visits. Response to treatment will be evaluated using RECIST criteria. Overall and
      progression free survival (OS and PFS) will be estimated using the Kaplan-Meier method.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Locally Advanced Inoperable Non-small-lung Cancer</condition>
  <arm_group>
    <arm_group_label>Valproic acid, Chemoradiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic acid</intervention_name>
    <description>800mg per day for entire period of RT</description>
    <arm_group_label>Valproic acid, Chemoradiotherapy</arm_group_label>
    <other_name>Sodium valproate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years.

          2. Newly-diagnosed, histologically or cytologically confirmed NSCLC.

          3. Inoperable stage IIIA-B disease

          4. KPS &gt; 60

          5. FEV1 &gt;1.2L

          6. No previous RT to chest

          7. No serious comorbid condition

          8. No treatment with biological response modifiers or cytotoxic agents within four weeks
             prior to study entry

          9. No participation in clinical trial using any investigational drug or device within
             four weeks prior to study entry

         10. No serious complication of malignant condition

         11. No previous or concurrent malignancy at other sites except cone biopsied in situ
             carcinoma of the uterine cervix and adequately treated basal cell or squamous cell
             carcinoma of the skin

         12. Adequate organ function as evidenced by the following peripheral blood counts or serum
             chemistries at study entry:

             Hemoglobin &gt; 9.0 Gm/dL WBC count &gt; 4.0x109/L Neutrophile count &gt; 1.5 cells x 109/L,
             Version 1, May 12, 2010 Platelet count &gt; 100 x 109/L, Creatinine &lt; 1.5 mg/dL Total
             bilirubin &lt; upper limit of normal (ULN) AST/SGOT &lt; ULN Calcium &lt; ULN

         13. Ability to sign informed consent

         14. Ability to attend follow-up visits

        Exclusion Criteria:

          1. Operable disease

          2. Metastases to contra-lateral mediastinal lymph nodes

          3. Distant metastases

          4. KPS &lt; 60

          5. FEV1 &lt; 1.2L

          6. Previous RT to chest

          7. Treatment with biological response modifiers or cytotoxic agents within four weeks
             prior to study entry

          8. Participation in clinical trial using any investigational drug or device within four
             weeks prior to study entry

          9. Major surgical procedure within two weeks prior to study entry

         10. Serious comorbid condition, inclusive but not limited to myocardial infarction within
             previous six months, uncontrolled cardiac arrhythmias, uncontrolled angina pectoris,
             active infection including acute hepatitis

         11. Serious complication of malignant condition

         12. Previous or concurrent malignancy

         13. Inadequate organ function as evidenced by the following peripheral blood counts or
             serum chemistries at study entry:

             Hemoglobin &lt; 9.0 Gm/dL WBC count &lt; 4.0x109/L Neutrophile count &lt; 1.5 cells x 109/L,
             Platelet count &lt; 100 x 109/L, Creatinine &gt; 1.5 mg/dL Total bilirubin &gt; ULN (upper
             limit of normal) AST/SGOT &gt; ULN Version 1, May 12, 2010 Calcium &gt; ULN

         14. Inability to sign informed consent

         15. Psychological, familial, sociological or geographical conditions which do not permit
             regular medical follow-up and compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantin Lavrenkov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soroka University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konstantin Lavrenkov, MD, PhD</last_name>
    <phone>972-86400537</phone>
    <email>constant@bgu.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantin Lavrenkov, MD, PhD</last_name>
      <phone>+97286400537</phone>
      <email>constant@bgu.ac.il</email>
    </contact>
    <contact_backup>
      <last_name>Julia Dudnik, MD</last_name>
      <phone>+97286400537</phone>
      <email>juliad@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Vladimir Gavrilov, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Dudnik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kerenr Rouvinov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <last_update_submitted>March 27, 2011</last_update_submitted>
  <last_update_submitted_qc>March 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Konstantin Lavrenkov, MD, PhD</name_title>
    <organization>Department of Oncology, Soroka University Medical Center</organization>
  </responsible_party>
  <keyword>Non-small-cell lung cancer</keyword>
  <keyword>Valproic acid</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

